D-8147 Duvelisib, Free Base, >99%

Synonyms : [IPI-145] [INK-1197]

Prices_reduced
  • Size
  • US $
  • £
  • ¥
  • 5 mg
  • 56
  • 46
  • 41
  • 6,200
  • Add to Cart Qty:
  • In stock
  • 10 mg
  • 84
  • 70
  • 61
  • 9,300
  • Add to Cart Qty:
  • In stock
  • 25 mg
  • 138
  • 115
  • 101
  • 15,300
  • Add to Cart Qty:
  • In stock
  • 50 mg
  • 185
  • 154
  • 136
  • 20,500
  • Add to Cart Qty:
  • In stock
  • 100 mg
  • 252
  • 210
  • 185
  • 27,900
  • Add to Cart Qty:
  • In stock
  • 200 mg
  • 410
  • 342
  • 301
  • 45,500
  • Add to Cart Qty:
  • In stock
  • 500 mg
  • 887
  • 741
  • 652
  • 98,400
  • Add to Cart Qty:
  • In stock

Note: Our Euro, Pound, and Yen prices are revised regularly to account for currency exchange rate fluctuations.

To receive a Quotation for catalog sizes of this product and/or any other products, please add them to your shopping cart and click on the “REQUEST A QUOTATION” box.
Click Here to Request a Quotation for Larger Quantities Click Here to see what Shipping and Handling Costs would be to Your Country
  • M.W. 416.86
  • C22H17ClN6O
  • [1201438-56-3]

Certificate of Analysis

  • Duvelisib, also known as IPI-145, is a potent inhibitor of phosphoinositide-3-kinase (PI3K) [delta] and PI3K [gamma]. It inhibits PI3K [delta] and [gamma] with Ki values of 23 and 243 pM, cell-free IC50 values of 2.5 and 27.4 nM, and cellular IC50 values of 1 nM and 43 nM, respectively. It was active in preclinical models of arthritis. Porter J.R., et al. "The potent phosphoinositide-3-kinase-(delta, gamma) inhibitor IPI-145 is active in preclinical models of arthritis and well tolerated in healthy adult subjects." http://infi.com/pdfs/ACR_ARHP2012.pdf
  • Duvelisib was active and well-tolerated in patients with relapsed/refractory peripheral and cutaneous T-cell lymphomas. Horwitz S., et al. "Preliminary Safety and Efficacy of IPI-145, a Potent Inhibitor of Phosphoinositide-3-Kinase-δ, γ in Patients with Relapsed/Refractory T-Cell Lymphoma." http://infi.com/pdfs/LuganoTcell.pdf
  • A phase I trial demonstrated that duvelisib was well tolerated and showed initial clinical activity in patients with indolent non-Hodgkin's lymphoma, mantle cell lymphoma, and chronic lymphocytic leukemia. Flinn I.W., et al. "Clinical Safety and Activity in a Phase 1 Trial of IPI-145, a Potent Inhibitor of Phosphoinositide-3-Kinase-{delta},{gamma}, in Patients with Advanced Hematologic Malignancies." Blood (ASH Annual Meeting Abstracts) 120: Abstract 3663 (2012).
  • Other CAS numbers previously assigned to IPI-145 free base, namely 1355213-59-0 and 1428465-12-6, have been deleted by CAS and are no longer in use.
  • Sold for laboratory or manufacturing purposes only; not for human, veterinary, food, or household use
  • This product is offered for R&D use in accordance with (i) 35 USC 271(e)+A13(1) in the U.S.; (ii) Section 69.1 of Japanese Patent Law in Japan; (iii) Section 11, No. 2 of the German Patent Act of 1981 in Germany; (iv) Section 60, Paragraph 5b of the U.K. Patents Act of 1977 in the U.K.; (v) Sections 55.2(1) and 55.2(6) and other common law exemptions of Canadian patent law; (vi) Section 68B of the Patents Act of 1953 in New Zealand together with the amendment of same by the Statutes Amendment Bill of 2002; (vii) such related legislation and/or case law as may be or become applicable in the aforementioned countries; and (viii) such similar laws and rules as may apply in various other countries.
  • Not available in some countries; not available to some institutions; not available for some uses.
550